throbber
Page 1
`
` UNITED STATES PATENT AND TRADEMARK OFFICE
`
` BEFORE THE TRADEMARK TRIAL AND APPEAL BOARD
`
` __________________________________
`
` MYLAN PHARMACEUTICALS INC., )
`
` MSN LABORATORIES PRIVATE LTD., )
`
` and MSN PHARMACEUTICALS INC., )
`
` Petitioners )
`
` vs. )
`
` BAUSCH HEALTH IRELAND LIMITED, )
`
` Patent Owner )
`
` ___________________________________
`
` CASE IPR2022-00722
`
` Patent 7,041,786
`
` - C O N F I D E N T I A L -
`
` Deposition of Stephen G. Davies, Ph.D.
`
` February 16, 2023
`
` 9:10 a.m.
`
` Reported by: Bonnie L. Russo
`
` Job No. 5696711
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`1 2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`MYLAN EXHIBIT - 1060
`Mylan Pharmaceuticals, Inc. v. Bausch Health Ireland, Ltd.
`IPR2022-00722
`
`PUBLIC VERSION
`
`

`

` Deposition of Stephen G. Davies, Ph.D.
`
` held at:
`
`Page 2
`
` Finnegan Henderson Farabow
`
` Garrett & Dunner, LLP
`
` 901 New York Avenue, N.W.
`
` Washington, D.C.
`
` Pursuant to Notice, when were present on behalf
`
` of the respective parties:
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`1
`
`2
`
`3 4 5 6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`PUBLIC VERSION
`
`

`

`
`
`Page 3
`
` A P P E A R A N C E S :
`
` O n b e h a l f o f t h e P e t i t i o n e r :
` J A D M I L L S , E S Q U I R E
` R I C H A R D T O R C Z O N , E S Q U I R E
` T A S H A T H O M A S , E S Q U I R E
` W I L S O N S O N S I N I G O O D R I C H & R O S A T I
` 1 7 0 0 K S t r e e t , N . W . , 5 t h F l o o r
` W a s h i n g t o n , D . C . 2 0 0 0 6
` j m i l l s @ w s g r . c o m
` r t o r c z o n @ w s g r . c o m
` t t h o m a s @ w s g r . c o m
`
` O n b e h a l f o f t h e P a t e n t O w n e r :
` K A S S A N D R A O F F I C E R , E S Q U I R E
` J U S T I N J . H A S F O R D , E S Q U I R E
` L A U R E N R O B I N S O N , E S Q U I R E
` F I N N E G A N , H E N D E R S O N , F A R A B O W ,
` G A R R E T T & D U N N E R , L L P
` 9 0 1 N e w Y o r k A v e n u e , N . W .
` W a s h i n g t o n , D . C . 2 0 0 0 1
` k a s s a n d r a . o f f i c e r @ f i n n e g a n . c o m
` j u s t i n . h a s f o r d @ f i n n e g a n . c o m
` l a u r e n . r o b i n s o n @ f i n n e g a n . c o m
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`1
`
`2 3
`
`4
`
`5
`
`6
`
`7
`
`8 9
`
`1 0
`
`1 1
`
`1 2
`
`1 3
`
`1 4
`
`1 5
`1 6
`1 7
`1 8
`1 9
`2 0
`2 1
`2 2
`
`PUBLIC VERSION
`
`

`

`
`
` C O N T E N T S
` EXAMINATION OF STEPHEN G. DAVIES, Ph.D. PAGE
` BY MR. MILLS 6
`
`Page 4
`
` EXHIBITS
`
` PREVIOUSLY MARKED EXHIBITS:
` Exhibit 1001 United States Patent
` 7,041,786 B2
`
` Exhibit 1006 Article entitled
` "Purification, cDNA
` sequence, and tissue
` distribution of rat
` uroguanylin"
` Exhibit 2012 Article entitled
` "Uroguanylin: Structure
` and activity of a second
` endogenous peptide that
` stimulates intestinal
` guanylate cyclase"
`
` Exhibit 2021 International Publication
` Number WO 01/25266 A1
` Exhibit_2024 Declaration of
` Stephen G. Davies, D.Phil.
` (Redacted)
` Exhibit 2024 Declaration of
` Stephen G. Davies, D.Phil
` (Unredacted)
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`1
`2
`3
`
`4 5 6
`
`7 8
`
`9
`
`10
`11
`
`12
`
`13
`14
`
`15
`
`16
`
`17
`
`18
`19
`
`20
`21
`
`22
`
`PUBLIC VERSION
`
`

`

`
`
` P R E V I O U S L Y M A R K E D E X H I B I T S ( C O N T I N U E D ) :
`
`Page 5
`
` E x h i b i t 2 0 2 7 S t u d y e n t i t l e d
`
` " S P - 3 0 4 : S t i m u l a t i o n
`
` o f I n t r a c e l l u l a r c G M P
`
` S y n t h e s i s i n T 8 4 C e l l s "
`
` ( E x h i b i t s b o u n d s e p a r a t e l y . )
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`1
`
`2 3
`
`4
`
`5 6 7 8 9
`
`1 0
`
`1 1
`
`1 2
`
`1 3
`
`1 4
`
`1 5
`
`1 6
`
`1 7
`
`1 8
`
`1 9
`
`2 0
`
`2 1
`
`2 2
`
`PUBLIC VERSION
`
`

`

`
`
`Page 6
`
` P R O C E E D I N G S
`
` (9:10 a.m.)
`
` STEPHEN G. DAVIES, Ph.D.,
`
` being first duly sworn, to tell the truth, the
`
` whole truth and nothing but the truth,
`
` testified as follows:
`
` EXAMINATION BY COUNSEL FOR PETITIONER
`
` BY MR. MILLS:
`
` Q. Good morning.
`
` A. Good morning.
`
` Q. Please state your name for the
`
` record.
`
` A. Stephen Graham Davies.
`
` Q. And please provide your address for
`
` the record.
`
` A. 7 Apsley Road, Oxford, OX2 7QX,
`
` United Kingdom.
`
` Q. Dr. Davies, do you understand that
`
` you are under oath today the same as if you
`
` were in court in front of a judge, correct?
`
` A. I understand that, yes.
`
`1
`
`2
`
`3 4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`PUBLIC VERSION
`
`

`

`
`
`Page 7
`
` Q. I'm going to discuss the rules of
`
` deposition just to make sure that we all are
`
` clear.
`
` So the first rule is that it's
`
` important that you and I don't speak over one
`
` another.
`
` Do you understand that?
`
` A. I understand that.
`
` Q. I will do my best not to interrupt
`
` you, and I will ask you to do the same for me.
`
` Does that make sense?
`
` A. Okay.
`
` Q. If your counsel interposes any
`
` objections, you still need to answer my
`
` question unless counsel instructs you not to
`
` answer the question.
`
` Do you understand that?
`
` A. I understand that.
`
` Q. If at any point you don't understand
`
` a question that I ask you, will you tell us?
`
` A. I will.
`
` Q. Okay. Is there any reason that you
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`PUBLIC VERSION
`
`

`

`
`
` can't give your best, full, accurate testimony
`
`Page 8
`
` today?
`
` A. No.
`
` Q. Dr. Davies, what did you do to
`
` prepare for your deposition today?
`
` A. I read through my declaration and
`
` some of the references therein in the patent.
`
` Q. Which references did you review in
`
` preparation for your deposition?
`
` A. I don't know. I don't recall. It
`
` was a random set.
`
` Q. Okay. Other than reviewing your
`
` declaration and a random set of references
`
` cited in your declaration, did you do anything
`
` else to prepare for your deposition today?
`
` A. I met with the attorneys yesterday.
`
` Q. For how long did you meet with the
`
` attorneys yesterday?
`
` A. I don't recall precisely. The -- it
`
` was morning and afternoon.
`
` Q. Other than meeting with the
`
` attorneys yesterday in preparation for your
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`PUBLIC VERSION
`
`

`

`
`
`Page 9
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
` deposition and the review of documents we've
`
` already discussed, did you do anything else to
`
` prepare for your deposition?
`
` A. I don't believe so.
`
` Q. Approximately how much time have you
`
` spent that will be billable to your client to
`
` prepare for your deposition today?
`
` MS. OFFICER: Object to form.
`
` THE WITNESS: I don't know. I keep
`
` an -- I send my accountant hours, and he
`
` prepares the bill. And so I don't keep track
`
` of the total.
`
` BY MR. MILLS:
`
` Q. Is it more than ten hours?
`
` A. It will be more than ten hours, yes.
`
` Q. Will it be more than 20 hours?
`
` A. Total since I started looking at
`
` this?
`
` Q. Right now we are just asking about
`
` preparation for the deposition.
`
` A. Oh, it was on the plane coming over
`
` and -- and whatever yesterday.
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`PUBLIC VERSION
`
`

`

`
`
`Page 10
`
` Q. Right. So what's your best
`
` estimate?
`
` A. 15 hours, 14 hours, something like
`
` that.
`
` Q. And you charge 450 British pounds
`
` per hour for the work; is that correct?
`
` A. That's correct.
`
` Q. Now I'm going to ask about a total
`
` for your work on this case. What's your
`
` estimate for the amount of time that you have
`
` billed or will be billable to your client for
`
` your work on this case?
`
` A. I --
`
` MS. OFFICER: Object to form.
`
` THE WITNESS: I can't -- I don't
`
` know the answer. I don't keep track.
`
` BY MR. MILLS:
`
` Q. Is it more than 20 hours?
`
` A. I'm sure it's -- it must be more.
`
` In total it must be more than 20 hours.
`
` Q. In total is it more than 40 hours?
`
` A. I really don't know.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`PUBLIC VERSION
`
`

`

`Page 11
`
` Q. Could it be as many as a hundred
`
` hours?
`
` A. I doubt it.
`
` Q. So your best estimate is that it's
`
` somewhere more than 20 and less than a hundred;
`
` is that correct?
`
` MS. OFFICER: Object to form.
`
` THE WITNESS: I don't know how much
`
` it was.
`
` BY MR. MILLS:
`
` Q. So you referred to your declaration
`
` and that you reviewed your declaration in
`
` preparation for your deposition today.
`
` Do you recall that testimony?
`
` MS. OFFICER: Objection to the
`
` extent it mischaracterizes.
`
` THE WITNESS: I read my declaration
`
` in preparation for this, yes.
`
` BY MR. MILLS:
`
` Q. In reviewing your declaration in
`
` preparation for your deposition, did you find
`
` anything in your declaration, any errors that
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`PUBLIC VERSION
`
`

`

`
`
`Page 12
`
` you need to fix?
`
` MS. OFFICER: Object to form.
`
` THE WITNESS: I don't think I found
`
` any errors. I think there was a typo.
`
` BY MR. MILLS:
`
` Q. So other than the typo, there is
`
` nothing about your declaration that needs to be
`
` changed; is that correct?
`
` A. You would need to show me my
`
` declaration. I can see -- I can look for what
`
` I'm -- I'm referring to and show you that.
`
` Q. Okay. So my question is: You
`
` mentioned a typo, so other than the typo that
`
` you found, is there any other error in your
`
` declaration that you found in your review when
`
` you were preparing for your deposition today?
`
` A. Only this -- only the one thing.
`
` Q. So is it fair to say that, sitting
`
` here today, you stand by everything that's
`
` written in your declaration other than the typo
`
` that you found?
`
` A. Yes. Yes.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`PUBLIC VERSION
`
`

`

`
`
`Page 13
`
` Q. Okay. Coming here today do you have
`
` any new opinions that you are prepared to give
`
` during your deposition that are not contained
`
` in your declaration?
`
` MS. OFFICER: Object to form.
`
` THE WITNESS: Not that I recall.
`
` BY MR. MILLS:
`
` Q. Dr. Davies, are you familiar with
`
` the '786 patent to Shailubhai?
`
` A. Yes.
`
` Q. And that's the patent that's at
`
` issue in this proceeding, correct?
`
` A. Correct.
`
` Q. Before signing your declaration, you
`
` reviewed the '786 patent; is that correct?
`
` A. That's correct.
`
` Q. Did you review the patent in its
`
` entirety?
`
` A. I read the patent, yes.
`
` Q. What portion of the patent did you
`
` turn to to understand what invention is at
`
` issue in this proceeding?
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`PUBLIC VERSION
`
`

`

`
`
`Page 14
`
` MS. OFFICER: Object to form.
`
` THE WITNESS: Well, I read the whole
`
` patent. I read the abstract, the claims, and
`
` then the whole patent, so I considered the
`
` whole patent.
`
` BY MR. MILLS:
`
` Q. Okay. You mentioned the claims in
`
` the patent.
`
` Do you have an understanding that
`
` the claims of the patent define the invention
`
` of the patent?
`
` MS. OFFICER: Object to form.
`
` THE WITNESS: Well, I understand
`
` that when we did a patent, you look at the
`
` claims in the context of the whole patent.
`
` MR. MILLS: Let's go ahead and hand
`
` out Exhibit 1001. This has been previously
`
` marked.
`
` MS. OFFICER: Thank you.
`
` BY MR. MILLS:
`
` Q. Dr. Davies, I have handed you what
`
` was previously marketed as Exhibit 1001. This
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`PUBLIC VERSION
`
`

`

`
`
`Page 15
`
` is the '786 patent that's at issue in this
`
` proceeding; is that correct?
`
` A. That's correct.
`
` Q. And on the very last page of Exhibit
`
` 1001, there is a listing of six claims; is that
`
` correct?
`
` MS. OFFICER: Object to the
`
` extent -- or, actually, mischaracterizes.
`
` THE WITNESS: It's on the
`
` penultimate page of the document you gave me,
`
` the last page of the patent. There are six
`
` claims, yes.
`
` BY MR. MILLS:
`
` Q. And you agree that the claims that
`
` are listed in columns 37 and 38 of the '786
`
` patent define the subject matter of the
`
` invention of the '786 patent?
`
` MS. OFFICER: Object to form.
`
` THE WITNESS: The claims -- a person
`
` of ordinary skill would read the claims in the
`
` context of the patent. We'd look at the whole
`
` of the patent.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`PUBLIC VERSION
`
`

`

`
`
`Page 16
`
` BY MR. MILLS:
`
` Q. Is there a difference between what
`
` the claims define as the invention of the '786
`
` patent and what the invention of the '786
`
` patent is according to the specification?
`
` MS. OFFICER: Objection. Calls for
`
` legal conclusion.
`
` THE WITNESS: I am a chemist, not a
`
` lawyer. So that's a legal question, not a
`
` science question.
`
` BY MR. MILLS:
`
` Q. So the reason for my question is to
`
` understand your analysis, what it was that you
`
` were evaluating for obviousness purposes.
`
` So is it fair to say that when you
`
` were evaluating the obviousness of the
`
` invention of the '786 patent that you were
`
` evaluating what is listed in the claims 1
`
` through 6?
`
` A. I evaluated what is in the claims 1
`
` to 6 in the context of the whole patent,
`
` including the specification.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`PUBLIC VERSION
`
`

`

`
`
`Page 17
`
` Q. Is there a difference between what
`
` is listed in the claims and the -- what you
`
` refer to as the context of the specification?
`
` MS. OFFICER: Objection. Calls for
`
` a legal conclusion.
`
` THE WITNESS: That's -- that's a
`
` legal question, not a science question.
`
` BY MR. MILLS:
`
` Q. What I am trying to understand is
`
` what it was that you were evaluating the
`
` obviousness of. So is there -- perhaps you can
`
` tell us.
`
` Please identify any context from the
`
` '786 patent that you relied on to interpret the
`
` meaning of the claims of the '786 patent?
`
` MS. OFFICER: Objection. Vague.
`
` THE WITNESS: I read -- as I've said
`
` previously, I read the whole patent. I read
`
` the claims, and then I considered the claims in
`
` the context of the whole specification.
`
` BY MR. MILLS:
`
` Q. Dr. Davies, you said earlier that
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`PUBLIC VERSION
`
`

`

`
`
`Page 18
`
` you reviewed the abstract of the '786 patent.
`
` Do you recall that?
`
` A. That's correct. I read the whole
`
` patent. That includes the abstract.
`
` Q. The first line of the abstract says:
`
` "A method of treatment of inflamed precancerous
`
` or cancerous tissue or polyps in a mammalian
`
` subject is disclosed."
`
` Do you see that?
`
` A. That's what it says.
`
` Q. And please take a look at Claim 1 of
`
` the '786 patent.
`
` A. Okay.
`
` Q. Does Claim 1 require a method of
`
` treatment of inflamed precancerous or cancerous
`
` tissue or polyps in a mammalian subject?
`
` MS. OFFICER: Objection. Legal
`
` conclusion.
`
` THE WITNESS: That's a legal
`
` question that I don't know how to answer since
`
` I'm not a lawyer. The claim is what it says.
`
` BY MR. MILLS:
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`PUBLIC VERSION
`
`

`

`
`
`Page 19
`
` Q. So, Dr. Davies, you evaluated the
`
` obviousness of claims 1 through 6 of the '786
`
` patent, correct?
`
` A. As it says in my report.
`
` Q. When you were evaluating the
`
` obviousness of Claim 1 of the '786 patent, was
`
` it your understanding that Claim 1 of the '786
`
` patent requires a method of treatment of
`
` inflamed precancerous or cancerous tissue or
`
` polyps in a mammalian subject?
`
` A. That's -- as I said previously,
`
` that's a legal question.
`
` Q. Well, I haven't asked --
`
` A. I don't need --
`
` Q. I'm sorry.
`
` A. -- I don't need that information to
`
` understand what Claim 1 says.
`
` Q. So that's my question. My question
`
` isn't what a legal conclusion is.
`
` My question is: What understanding
`
` to the -- that you were bringing to Claim 1 as
`
` you were evaluating it for its obviousness?
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`PUBLIC VERSION
`
`

`

`
`
`Page 20
`
` A. Whether I understand what Claim 1
`
` says.
`
` Q. Does Claim 1, as you understand it,
`
` require a method of treatment of inflamed
`
` precancerous or cancerous tissue or polyps in a
`
` mammalian subject?
`
` A. I think Claim 1 is for a peptide of
`
` the given sequence, and that's all.
`
` Q. When you say "Claim 1 is for a
`
` peptide of a given sequence and that's all,"
`
` what sequence are you referring to?
`
` A. The one that's named in Claim 1.
`
` Q. And which sequence that?
`
` A. ID No. 20.
`
` Q. And can you point us to where the
`
` '786 patent discloses the Sequence ID No. 20
`
` that's the peptide claimed in Claim 1 of the
`
` '786 patent?
`
` MS. OFFICER: Object to form.
`
` THE WITNESS: So I look to Column
`
` 15, Line 57 where it identifies that sequence
`
` as the peptide SP304, which is a purified
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`PUBLIC VERSION
`
`

`

`
`
`Page 21
`
` peptide creating 95 percent purity with the
`
` sequence that is on Column 35. There are going
`
` to be 20 lines on this one, but about all the
`
` way down the page, it says -- oh, that's Line
`
` 400. Oh, darn it. It says 400 sequence 20 and
`
` then gives a sequence.
`
` BY MR. MILLS:
`
` Q. Okay. So, Dr. Davies, when you were
`
` providing your opinions in your declaration for
`
` this case, was it your understanding that Claim
`
` 1 requires a peptide purified to 95 percent
`
` purity of an amino acid sequence of Sequence ID
`
` No. 20?
`
` MS. OFFICER: Object to form.
`
` THE WITNESS: I'm -- I'm reading the
`
` claim in the context of the patent, and the
`
` patent describes a peptide of this sequence
`
` that has been purified to greater than 95
`
` percent purity.
`
` BY MR. MILLS:
`
` Q. So that's the reason for my
`
` question.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`PUBLIC VERSION
`
`

`

`
`
`Page 22
`
` So you pointed to the 95 percent
`
` purity, and my question is: Is it -- when you
`
` were providing your opinions for your
`
` declaration, were you interpreting Claim 1 to
`
` require that the peptide be purified 95 percent
`
` purity?
`
` A. In the context of the patent, it has
`
` been purified to 95 percent purity. Whether it
`
` requires that for that claim, that's a legal
`
` question.
`
` Q. So, again, I'm not asking you for a
`
` legal conclusion, but I am entitled to know
`
` what it was that you were evaluating the
`
` obviousness of.
`
` And so I understand that you've
`
` testified already that there is disclosure of
`
` purifying a peptide to 95 percent purity. But
`
` what I need to know is for your opinions that
`
` you offered, do those opinions turn on a
`
` construction that the claimed peptide must be
`
` purified to 95 percent purity.
`
` MS. OFFICER: Objection.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`PUBLIC VERSION
`
`

`

`
`
`Page 23
`
` Argumentative. Legal conclusion.
`
` THE WITNESS: I am saying that when
`
` I evaluated this patent, I looked at Claim 1 in
`
` context of the patent as a whole. And the
`
` patent talks about the sequence which is on
`
` Column 35, and also that sequence is referred
`
` to in Column 15 as being a purified peptide.
`
` BY MR. MILLS:
`
` Q. So I still don't have an answer to
`
` my question. You've told us that the claim
`
` recites the Sequence ID No. 20, and you've told
`
` us that Sequence ID No. 20 appears in Column 35
`
` of the patent. And you've told us that the
`
` patent also discloses purifying Sequence ID
`
` No. 20 to 95 percent purity.
`
` What I need to know is whether for
`
` the purposes of your opinions in your
`
` declaration whether it was your understanding
`
` that the claim requires 95 percent purification
`
` of the peptide.
`
` MS. OFFICER: Objection. Asked and
`
` answered. Mischaracterizes. Legal conclusion.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`PUBLIC VERSION
`
`

`

`
`
`Page 24
`
` Argumentative.
`
` THE WITNESS: As I have explained, I
`
` looked at Claim 1. It gives a sequence number.
`
` I find the sequence number in Column 35, and I
`
` find the sequence number also in -- at least in
`
` Column 15 where 15 describes purifying that
`
` peptide of that sequence to greater than 95
`
` percent purity.
`
` BY MR. MILLS:
`
` Q. So, Dr. Davies, what invention did
`
` you evaluate for your opinions regarding Claim
`
` 1? Was it an invention of a peptide that's
`
` purified to 95 percent?
`
` MS. OFFICER: Object to form.
`
` THE WITNESS: As I have said, it's
`
` -- I evaluated the Claim 1 which names the
`
` sequence in the light of the patent as a whole
`
` which gives a sequence and it gives a
`
` purification of a -- of a peptide that is
`
` greater than 95 percent.
`
` BY MR. MILLS:
`
` Q. So, Dr. Davies, you're telling us
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`PUBLIC VERSION
`
`

`

`
`
`Page 25
`
` that the specification gives a peptide that's
`
` purified to greater than 95 percent, correct?
`
` MS. OFFICER: Object to form.
`
` THE WITNESS: It describes that
`
` peptide greater than 95 percent pure.
`
` BY MR. MILLS:
`
` Q. You agree that the words in Claim 1
`
` don't say purified anywhere, correct?
`
` A. Claim 1 does not say that, but I --
`
` as I said, I evaluate -- I evaluated the claims
`
` in the light of the whole specification.
`
` Q. So the way that you were evaluating
`
` Claim 1 is based on the specification you were
`
` reading in the word "purified to 95 percent";
`
` is that correct?
`
` MS. OFFICER: Objection.
`
` Mischaracterizes.
`
` THE WITNESS: I am reading Claim 1
`
` in the context of the patent, which gives me
`
` the sequence and then gives me, in Column 15,
`
` that it's a peptide that is purified to greater
`
` than 95 percent.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`PUBLIC VERSION
`
`

`

`
`
`Page 26
`
` BY MR. MILLS:
`
` Q. But, Dr. Davies, when you evaluated
`
` Claim 1 for obviousness, your evaluation
`
` required that the peptide of Claim 1 be
`
` purified to a purity greater than 95 percent;
`
` is that correct?
`
` MS. OFFICER: Objection. Asked and
`
` answered. Mischaracterizes.
`
` THE WITNESS: I evaluated Claim 1 in
`
` the context of the whole specification which
`
` includes the sequence on Column 35 and on
`
` Column 15 where it says it's a purified peptide
`
` at greater than 95 percent.
`
` BY MR. MILLS:
`
` Q. So, Dr. Davies, you've answered
`
` several times about -- that there is a
`
` disclosure in the specification of a peptide
`
` that is purified to 95 percent. What I don't
`
` have from you still is a clear answer as to
`
` whether when you were evaluating the
`
` obviousness of Claim 1 you were interpreting
`
` Claim 1 to require purification of 95 percent.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`PUBLIC VERSION
`
`

`

`
`
`Page 27
`
` And that's what -- I am entitled to that
`
` answer.
`
` So can you please tell me whether
`
` for your obviousness determination you
`
` interpreted Claim 1 to require purification to
`
` 95 percent?
`
` MS. OFFICER: Objection. Asked and
`
` answered.
`
` THE WITNESS: I have explained as
`
` best I can how I evaluated Claim 1 which is in
`
` the context of what it says in Claim 1 and in
`
` the specification as I've described.
`
` MR. MILLS: I'm going to ask the
`
` witness to leave the room for just a moment. I
`
` need to speak with opposing counsel on the
`
` record.
`
` BY MR. MILLS:
`
` Q. Can you just step out for just a
`
` moment.
`
` MR. HASFORD: No. No. What do you
`
` need to speak with us on the record about?
`
` MR. MILLS: So, first of all, I need
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`PUBLIC VERSION
`
`

`

`
`
`Page 28
`
` to know which counsel is defending the
`
` deposition because there are two counsel
`
` speaking --
`
` MR. HASFORD: No. It's not --
`
` MR. MILLS: -- and it's
`
` distracting -- well, there is. Every time I
`
` ask a question, you speak and then she speaks.
`
` MR. HASFORD: I don't speak. I
`
` whispered some things to her, which I'm
`
` entitled to do so...
`
` MR. MILLS: But it's distracting to
`
` the witness because you have a very visible
`
` reaction every time there is a question asked.
`
` MR. HASFORD: He can't see me. I am
`
` sitting on this side of the table, and he is
`
` not looking over here, and you know he is
`
` not --- -
`
` MR. MILLS: You're making --
`
` MR. HASFORD: -- so quit
`
` mischaracterizing things --
`
` MR. MILLS: You're making --
`
` MR. HASFORD: -- you are
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510 ~ 202-803-8830
`
`PUBLIC VERSION
`
`

`

`
`
`Page 29
`
` mischaracterizing things. You know it, and you
`
` are not entitled to sit here and harass the
`
` witness like you are doing --
`
` MR. MILLS: So --
`
` MR. HASFORD: -- if you want to the
`
` ask him stuff about his declaration, show him
`
` his declaration and ask him stuff about his
`
` declaration.
`
` MR. MILLS: I am not harassing the
`
` witness --
`
` MR. HASFORD: Yes, you are.
`
` MR. MILLS: -- I am not
`
` mischaracterizing things --
`
` MR. HASFORD: You sure are.
`
` MR. MILLS: -- and there needs to be
`
` one counsel from your side who is -- who is
`
` defending the deposition.
`
` MR. HASFORD: Which -- which is.
`
` It's Kassie. It's not me.
`
` MR. MILLS: Okay.
`
` MR. HASFORD: And I am entitled to
`
` whisper stuff to her.
`
`1
`
`2
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`17
`
`18
`
`19
`
`20
`
`21
`
`22
`
`Veritext Legal Solutions
`215-241-1000 ~ 610-434-8588 ~ 302-571-0510

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket